Simile Raises $200 Million in Series B at $2 Billion Valuation
Simile announced a $200 million Series B at a $2 billion valuation, led by Greenoaks. Index Ventures, Hanabi, Bain Capital Ventures, CVS Health Ventures and Definition participated in the round.
The company is building a foundation model designed to simulate human behavior and predict reactions to specific scenarios. Currently in production for enterprise clients such as CVS, Deloitte and Gallup, the platform uses generative agents to let organizations test business decisions before implementation.
From the sources (8 posts)
@percyliangIt's time to scale that Simile. Our ambition is to build a foundation model that can predict what anyone will do in any situation. Research-wise, Simile in 2026 for simulation is like OpenAI in 2019 for AI assistants - signs of life, a pa
@percyliangRT @joon_s_pk: Five months ago, we launched @simile_ai with the belief that simulation would become a new way for the world to make decisio…
@tri_daoCongrats to this super ambitious team
@srimuppidiRT @simile_ai: We’re building a future where people make better decisions today, by simulating how people will think, decide, and behave be…
@srimuppidiRT @Techmeme: Simile, which offers "agentic twins" of real people to assess companies' products, brands, and services, raised $200M led by…
@stanfordnlpRT @percyliang: It's time to scale that Simile. Our ambition is to build a foundation model that can predict what anyone will do in any si…
@indexventuresWe’re thrilled to double down on our investment in @joon_s_pk and @simile_ai with today’s $200M Series B. Simile is building the first AI simulation of society – generative agents that let organizations test their biggest decisions before
@simile_aiToday we’re announcing our Series B. We’ve raised $200M at a $2B valuation from Greenoaks with participation from Index Ventures, Hanabi, A*, Bain Capital Ventures, CVS Health Ventures, and Definition. Our mission is to simulate all eight